These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 19474163

  • 1. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P.
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [Abstract] [Full Text] [Related]

  • 2. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC, Schuler M.
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y, Lampkin T.
    Clin Cancer Res; 2010 Jan 15; 16(2):384-9. PubMed ID: 20068088
    [Abstract] [Full Text] [Related]

  • 5. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.
    McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, Carpenter L, Mackenzie M, Taylor P, Walkinshaw M, Fischer PM, Glover D.
    Nat Chem Biol; 2006 Nov 15; 2(11):608-17. PubMed ID: 17028581
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selectivity-determining residues in Plk1.
    Kothe M, Kohls D, Low S, Coli R, Rennie GR, Feru F, Kuhn C, Ding YH.
    Chem Biol Drug Des; 2007 Dec 15; 70(6):540-6. PubMed ID: 18005335
    [Abstract] [Full Text] [Related]

  • 8. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
    Wäsch R, Hasskarl J, Schnerch D, Lübbert M.
    Recent Results Cancer Res; 2010 Dec 15; 184():215-8. PubMed ID: 20072841
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G.
    Clin Cancer Res; 2010 Sep 15; 16(18):4666-74. PubMed ID: 20682708
    [Abstract] [Full Text] [Related]

  • 11. PLK1 as an oncology target: current status and future potential.
    McInnes C, Wyatt MD.
    Drug Discov Today; 2011 Jul 15; 16(13-14):619-25. PubMed ID: 21601650
    [Abstract] [Full Text] [Related]

  • 12. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S, Musacchio A.
    Curr Biol; 2007 Apr 17; 17(8):R280-3. PubMed ID: 17437704
    [Abstract] [Full Text] [Related]

  • 13. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
    Cancer Res; 2009 Sep 01; 69(17):6969-77. PubMed ID: 19690138
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K, Becker S, Matthess Y.
    Expert Opin Drug Discov; 2015 Jan 01; 10(1):1-8. PubMed ID: 25263688
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
    Kumar S, Kim J.
    Biomed Res Int; 2015 Jan 01; 2015():705745. PubMed ID: 26557691
    [Abstract] [Full Text] [Related]

  • 19. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.
    Medema RH, Lin CC, Yang JC.
    Clin Cancer Res; 2011 Oct 15; 17(20):6459-66. PubMed ID: 22003073
    [Abstract] [Full Text] [Related]

  • 20. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
    Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR.
    Cancer Res; 2011 Feb 15; 71(4):1385-95. PubMed ID: 21303981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.